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INTRODUCTION
Semen examination is the cornerstone of the evalu-
ation of male fertility potential. Despite its apparent 
simplicity, it is a complex series of assessments with 
highly variable results that are subject to interpreta-
tion. The semen analysis is used to gauge reproductive 
potential and guide the clinician in management of 
the infertile couple. Over the past 40 years, the World 
Health Organization (WHO) Infertility Task Force has 
attempted to standardize the methodology of semen 
examination so as to bring uniformity and relevance 
to the test. The 1st edition of the “Laboratory Manual 
for the Examination and Processing of Human Semen” 
was published in 1980. Since then, four more editions 
of the WHO manual have been published, each at-
tempting to reflect global male population demograph-
ics, to address limitations from previous versions, and 
to incorporate technological and scientific evolution in 
the field of reproduction. Currently, the 5th edition of 
the WHO manual, published in 2010, is implemented 
worldwide, and is considered one of the most used, yet 
contested documents in the field of male infertility [1].
In March 2021, the WHO released a preliminary 
draft of the 6th edition of its manual for public review 
and suggestions (https://www.who.int/publications/
i/item/9789241547789). Essentially, the new manual 
comprises three parts: semen examination; sperm 
preparation and cryopreservation; and quality control 
and assurance. The procedures for semen examination 
include basic (routine) examinations, extended exami-
nations (which may be used by laboratories or clini-
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cians in certain situations), and advanced tests (which 
are not currently recommended for routine use and are 
primarily for research purposes).
The 6th edition has presented the basic examina-
tion in a step-by-step and temporal manner, so that 
it can be reproduced precisely in any laboratory with 
the required equipment and expertise. The sections on 
extended and advanced examinations have been com-
pletely revamped in concordance with current clinical 
practice, with many older tests being abandoned and 
new tests being adopted.
The purpose of this mini review and commentary 
is to familiarize fertility specialists with the principal 
changes proposed in the anticipated 6th edition of the 
WHO manual for human semen analysis. The advan-
tages, limitations and clinical implications of these 
changes are discussed.
1.  Use of decision limits to identify abnormal 
ejaculates
The most important change proposed in the 6th edi-
tion is the adoption of decision limits to differentiate 
normal from abnormal ejaculates. The editors of the 
6th edition acknowledge that the reference ranges de-
scribed in the 5th edition should be abandoned as they 
are of limited value in differentiating fertile from in-
fertile men.
The 5th edition WHO manual utilized a population 
of 1,800 fertile men to obtain the reference distribu-
tions for semen parameters [1]. The lower 5th percen-
tile was used to define the reference values for normal 
semen parameters. While the 5th percentile is com-
monly utilized as a statistical approach to determine 
cut-off norms in medical tests, this resulted in much 
controversy when applied to male fertility [2]. It has 
been argued that the 5th percentile is not applicable 
to assign normality in this case and proves unable to 
discriminate between fertile and infertile patients [3]. 
Several studies reported a shift of fertility status from 
abnormal to normal in 15% to 44% of patients by just 
using the 5th edition norms instead of the 4th edition 
[4-7]. It was therefore proposed that WHO reference 
ranges did not adequately reflect fertility dynamics of 
the male partner, with several investigators and cli-
nicians believing that normal values were above the 
lower 5th percentile. With these limitations in mind, 
the editors of the 6th edition suggested using differ-
ent reference limits because the previous reference 
ranges fail to differentiate fertile from infertile men 
[8]. Decision limits were introduced by Guzick et al [9], 
who proposed a two-level reference range narrative by 
defining an intermediate group of values. According 
to their data the sub-fertile population demonstrated 
a sperm concentration below 13.5×106/mL, sperm motil-
ity less than 32% and typical forms below 9%. Yet, the 
normal fertile subgroup had a sperm concentration 
greater than 48×106/mL, sperm motility over 63%, and 
normal morphology above 12%. Values between these 
two levels were categorized as intermediate fertility [9].
The 5th edition has been criticized for neglecting 
the female factor as an important confounder [3] and 
for both over- and under-representation of various 
regions of the world [4]. The editors of the 6th edition 
have acknowledged these limitations (Appendix 8.1 of 
the manual) and stipulated that semen examination 
cannot strictly differentiate between pathological and 
normal samples. Moreover, they recognize that using 
the lower 5th percentile is not the correct approach to 
identify normal or abnormal semen samples, and that 
semen analysis alone cannot predict fertility as this 
depends on multiple variables, particularly, female fac-
tors.
Hence, the “normal” reference values of the 5th edi-
tion have been replaced by “decision limits” in the 
6th edition. These are classified as “normal”, “border-
line”, and “pathological”. A “normal” concentration is 
≥20×106/mL, “borderline” lies between 10 to 20×106/mL, 
and “pathological” is <10×106/mL. For motility “normal” 
is defined as ≥50% progressively motile sperm, “border-
line” is 35% to 49% progressively motile, while a “path-
ological” sample is defined as <35% progressively motile 
sperm. Morphology has been categorized as “normal” 
when typical forms are ≥14%, “borderline” is between 
4% and 13% and “pathological” morphology is below 4%. 
Additionally, the 6th edition states that sperm antibod-
ies are not the sole cause of agglutination as this may 
be caused by different pathologies. Therefore, sperm 
antibody binding below 50% is considered “normal”; it 
is “borderline” between 50% to 79%, and “pathological” 
when ≥80%.
The introduction of the “decision limits” concept is 
an attempt to emphasize that the purpose of the semen 
examination is not to label a man as fertile or infer-
tile, but rather to decide next steps in terms of further 
evaluation and treatment. The current limits are still 
arbitrary and future studies with clinical outcomes in 
 Hussein Kandil, et al: WHO Sixth Edition Laboratory Manual: A Helicopter View
579www.wjmh.org
the various groups will help refine these limits. The 
creation of a “borderline” group will have significant 
clinical implications as many men whose sample would 
previously have been labeled as normal using the 5th 
edition criteria, will now be classified as “borderline” 
and be eligible for therapeutic interventions. Clinicians 
can still offer hope for natural pregnancy in these 
cases before opting to pursue ART. The impact of this 
classification shift will likely be significant in clinical 
practice. If we now apply the new criteria and deem 
men with parameters below the new “normal” thresh-
old (“borderline”+“pathological”) as infertile, we will 
suddenly increase the number of infertile men in our 
practices.
Interestingly, the upcoming manual presents revised 
reference values based on combined data of fertile men 
(with time to pregnancy less than 12 months) from the 
2010 manual (5th edition) and by including released 
data from studies published until 2020. The 6th edition 
has included data from 5 additional studies (with 1,789 
more male subjects) to those used in the 5th edition. 
The five new studies have incorporated data from two 
regions in Europe, one from Africa and two from Asia, 
although notably 1,200 out of 1,789 participants origi-
nate from China alone, therefore skewing the refer-
ence values towards normality of specific geolocations 
that do not necessarily apply in different populations.
2. Change in motility grading system
A criticism of the 5th edition was the decision to 
eliminate the reporting of rapidly progressive motility, 
and the editors of the 6th edition have now reverted 
back to a four-category classification as follows:
Rapidly progressive: ≥25 μm/s, or at least half tail 
length per second.
Slow progressive: 5 to <25 μm/s, or at least one head 
length to less than half tail length/sec.
Non progressive: <5 μm/s, or less than one head 
length.
Immotile: no tail movement.
A return to the earlier classification of the 4th edi-
tion of WHO manual for sperm motility [10] is a wel-
come improvement as it allows a better characteriza-
tion of motility and may provide additional prognostic 
information.
3. Sperm DNA fragmentation testing
The editors of the 6th edition should be commended 
for introducing tests of sperm DNA fragmentation 
(SDF) in the manual. The techniques of the various 
SDF tests (TUNEL and Comet assays, Sperm Chro-
matin Dispersion test, and Acridine Orange flow cy-
tometry) have been described and notes on the clinical 
interpretation of these assays have been included. The 
editors have also provided suggested thresholds for 
clinical decision-making. They state that “the evalua-
tion of SDF could constitute an important addition in 
the work-up of male infertility”. However, the editors 
of 6th edition suggest that the Comet assay should not 
be used in clinical practice because of an important de-
gree of inter-laboratory variation.
The application of sperm DNA tests in clinical prac-
tice remains controversial [11]. This controversy stems 
in part from the modest predictive value of SDF tests 
in reproduction and the multitude of available tests 
with variable thresholds and inter-lab variability.
The editors of the manual have not addressed the 
clinical value of these assays and have provided no 
guidance as to the indication for testing. Moreover, 
they have not addressed the limitations of these as-
says and have provided conflicting information on test 
thresholds (2 thresholds were listed for each of these 
assays). A revision will be needed to better guide the 
andrologist/clinician regarding the utility of these im-
portant assays [12].
4. Reactive oxygen species (ROS) testing
The 6th edition recognizes the increasing clinical 
relevance of seminal oxidative stress by dedicating a 
section to the methods assigned for ROS testing. Pos-
sibly due to the limited availability of such testing, this 
assessment has been incorporated under “Advanced 
Examination” section, suggesting that this should still 
be considered a research tool. However, given the large 
number of recent papers on the reproductive impact of 
oxidative stress and the clinical utility of ROS testing, 
along with the description of Male Oxidative Stress 
Infertility (MOSI) as a clinical entity [13], one may 
consider ROS testing as part of the extended semen ex-
amination in clinical practice.
CONCLUSIONS
The 6th edition is a step forward in our understand-
ing of the complex subject of male infertility through 
evaluation of the human ejaculate. Several objections 
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to the 5th edition have been addressed in the 6th edi-
tion, though areas of controversy remain. For the cli-
nician, the most notable change is the introduction of 
“decision limits” rather than reference ranges, and the 
endorsement of SDF as an extended seminal test that 
can be ordered in certain clinical situations. For the 
laboratory personnel, the manual has been streamlined 
to facilitate a step-by-step examination with several old 
tests being abandoned, while several new tests have 
been introduced. The long-awaited 6th edition will be 
read and followed with great interest by everyone in-
volved in the care of male reproductive health.
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